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Introduction
Anti-cancer Ti IV L n complexes are a current 'hot' area in bioinorganic chemistry. 1,2 They are attractive due to potential lower toxicity towards normal tissues (than traditional anti-cancer agents), and also due to an ability to tune cellular action through appropriate ligand choice. The high activities and multiple mechanisms of action shown by 'new generation' titanium-based species offer exciting potential for future clinical trial candidates; both in their own right and in combination with other therapeutic agents. This tutorial review is a 'primer' aimed at newcomers from the chemical sciences to this area who do not necessarily have any cancer biology background. A key requirement for any new drug to reach the clinic is that an active agents' precise molecular and biological target(s) must first be well defined (the so called 'mechanism of action'). Attaining this position for titanium-based pro-drugs is at the core of the discussion herein as it is the current bottleneck in developing 'in clinic' Ti-based therapies. The key issues are: (i) titanium anti-cancer agents can present opaque or conflicting biological data regarding their mechanisms of action and (ii) the precise structures of the active aqueous titanium species involved (and interaction with their exact biological targets) are still poorly defined, even though recent findings include many active compounds stable in water. Titanium(IV) species are potent Lewis acids which can interfere with a wide range of biological (Lewis basic) functions in any of the ~2 00
(cancer) cell types in the human body. Thus, perversely to the uninitiated, a single cytotoxic (cell 'killing') titanium complex can engender very different growth behaviour profiles against a range of cancer cell lines (Figure 1 ). The time-consuming nature of biological studies frequently limits the number of cell lines studied in an individual paper to a handful (at best). This can all too easily lead to over interpretation, and most particularly overgeneralisation of results (to other cell lines), posing risks for both the review writer (and new researchers) seeking to make general recommendations for improved titanium therapeutics. 50 (sometimes related GI 50 is used ‡) is typically measured by cell staining, e.g. with the tetrazolium reagent MTT after exposure to 1 for a pre-selected time.
For this reason we start this tutorial with an overview of 'mode of action' data attained for titanocene dichloride, TiCl 2 Cp 2 (Cp; = η-C 5 H 5 ) 2 (1) during the early 'discovery' period 1979-2005, together with a summary of critical chemical biology of relevance to mode of action discovery. This is followed by an outline of more recent experiments (ca. 2005 onwards) indicating that alternative molecular targets might be perturbed, at least by complexes distinct from Cp 2 TiCl 2 , and that additional biological modes of action conclusions can be drawn (Section 3). After a discussion of contemporary mechanistic tools available for the identification of the active titanium therapeutic species and validation of biological modes of action (Section 4) we suggest some potential future paths and strategies for putative therapeutics (Section 5).
Early titanium anti-cancer 'mode(s) of action' suggestions
In the wake of Rosenburg's seminal discovery (1965-69) of cancer inhibition by cis-PtCl 2 (NH 3 ) 2 (cisplatin) Köpf and Köpf-Maier reported the intuition-driven discovery of apparently related cytostatic (inhibition of cell growth) activity for the metallocene titanocene dichloride (1) in 1979. 3 Finally, 1 reached Phase II clinical trial in the 1990s but did not progress due to lack of in patient efficacy. Initial mode of action studies on 1 focused extensively on Ehrlich ascites tumours in mouse models (which presented highly encouraging 'cure' outcomes). DNA-binding, akin to cisplatin, was initially suggested by Köpf-Maier on the basis of: (i) suppression of synthesised DNA/RNA in tritium-labelled thymidine/uridine take up studies over 48 h, and (ii) the observation of apparent 'high levels' of titanium (in nucleic acid rich regions of cells exposed to 1) by X-ray energy loss spectroscopy (EELS). Unfortunately, the low intensity of the EELS signals observed forced Köpf-Maier to use very high (up to 10 mM) concentrations of 1 (20-25 × the IC 50 in this cell line) to detect any signal at all. Subsequent fluorescence studies of V79 hamster lung cells treated with Cp 2 TiCl 2 (100 μM) showed no significant difference in Ti-uptake compared to those not exposed (or indeed to those treated with other non-Ti metallocenes). 4 However, on the basis of the above experiments Ti uptake and intracellular delivery to a DNA target was typically assumed and proved a popular target for subsequent investigations and interpretations.
Neutral 1 is very insoluble (< 5 μM) in water or cellular growth media and forms colloidal suspensions (even when genuine DMSO solutions of 1 are then subjected to subsequent aqueous dilution Cisplatin (and its derivatives) are archetypal DNA interfering drugs, often used as reference compounds in anticancer research. The limitations of such platinum-based drugs include: efficacy against only a narrow range of tumours, acquired or intrinsic resistance, nephroand gastrointestinal toxicity, nausea and bone marrow suppression. Alternatives are highly desired. There are clear indications that the mechanism of action of 1 is different from DNA coordinating cisplatin, as evidenced by differences in their nucleic acid metabolism and in the relative efficacy of 1 vs. cisplatin against the multiple different cell lines of the USA National Cancer Institute (NCI-60). † Additionally, 1 significantly overcomes acquired cisplatin resistance in some cell lines, 11 e.g. 1 is still active in two human ovarian carcinoma cell lines (A2780CP and CH1-cisR) that are highly resistant to cisplatin. As cisplatin cytotoxicity is attained through DNA binding, cross-linking and ultimately strand breaks disrupting DNA replication and transcription, the resistance in the ovarian cell lines is directly related to an increased ability in the cancer cell to repair Pt-induced DNA damage. As 1 is able to induce growth inhibitory activity in these same cell lines, the mode of action of 1 is less likely be related to formation of DNA adducts. Model Lewis acid/base metal-DNA solution binding experiments, using tritium ( 3 H) labelled Cp ligands in 1 and isolated salmon testes DNA, allowed the average Ti-to-Cp ratio in the resultant DNA adducts to be determined. Reactions at pH 5.3 led to 'Cp 2 Ti' binding, however, those at (more biologically relevant) pH 7 led to mostly to 'CpTi' adhesion and some (ca. 15%) non-Cp titanium species. The Ti uptake is rather slow (>2-6 h, pH 5-7 for 10 mM 1), as monitored by ICPMS, and no information is gained about potential site(s) of binding. 12 The type of cell death induced by 1 or other titanium-anticancer agents can also be a hallmark of its mode of action, so these are now briefly overviewed ( Figure 3 ). Depending on the external stimuli provided to the cell (by the anti-cancer, or indeed any other agent) three major forms of programmed cell death (PCD) can occur: apoptosis (type 1), autophagy (type 2) or regulated necrosis (type 3). All three types can be characterised by cellular morphology changes and biochemical/biomolecular alterations ( Figure 3 ).
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Apoptosis is the most common form of programmed cell death suggested for 1. Apoptotic cells undergo cell shrinkage, membrane blebbing (formation of cell membrane protrusions), DNA chromatin condensation, nuclear fragmentation and formation of apoptotic bodies. Autophagy (type 2 PCD) is a self-degradative process of programmed cell death. The initial step in autophagy is the formation of an isolation membrane, a small lipid bilayer membrane structure called a phagophore. The phagophore then expands in order to be loaded with intra-cellular cargo such as protein aggregates, organelles and ribosomes. This results in the formation of an autophagosome, a spherical double-membraned structure containing sequestered cargo. The loaded autophagosome then fuses with a spherical vesicle (lysosome) containing hydrolytic enzyme proteases, resulting in vesicle content degradation. Immunoblotting, immunoprecipitation and/or immunofluorescence analyses of key proteins that interact with the human autophagic machinery (most notably LC3, BECN1 and p62/SQSTM1) can allow detection of autophagy as a possible 'mode of action'.
14 It has been suggested to be involved for the fluoro analogue of 1 (Cp 2 TiF 2 ) 15 and in agglomerated TiO 2 nanoparticles (diameter ~1 000 nm). 16 Necroptosis (type 3 PCD). Necrosis is a form of cell death that is morphologically characterised by cellular swelling, rupture of the plasma membrane and loss of cytoplasmic contents. Inflammatory necrotic cell death is normally classified as a non-PCD. However, necrotic PCD is known and termed necroptosis to distinguish it. This PCD is controlled by specific signal pathways and metabolic breakdown of signal molecules. Cytotoxic agents have been reported to induce necroptosis when a cell cannot die via (type 1) apoptotic pathways. Among other related atypical cell death modes of relevance to titanium anti-cancer agents, paraptosis (which can be considered as a form of type 3 PCD), is of importance. It is both morphologically and biochemically distinct from apoptosis (no common morphological hallmarks) and is associated with extensive cytoplasmic vacuolisation and mitochondrial swelling resulting in cell rupture ( Figure 3Ⱡ ). 17 Park reported vacuolisation, dilated ER and mitochondria in MH-S murine alveolar macrophages, by TiO 2 nanosheets (ca. 400 × 400 × 2 nm) and concluded that induced paraptosis and late onset apoptosis were the mechanisms of action.
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Even for the non-biologist, understanding the mechanistic links between PCD and cell division (the cell cycle) is of fundamental importance in developing effective routes to anti-cancer therapy.
For example, cells respond to DNA damage by halting cell cycle progression. During such arrests, the cell 'decides' whether the DNA damage can be repaired. Multiple DNA repair mechanisms have evolved to ensure the integrity of genetic material (breakdown in DNA repair enzymes can predispose individuals to cancer). If DNA damage is extensive, the cells may trigger apoptosis. For example, the p53 gene is a tumour suppressor gene is activated in response to diverse cellular stresses such as DNA damage, reduced oxygen levels and increased levels of tumour-gene expression. The p53 protein binds to DNA which in turn stimulates another gene to produce a protein (p21) that interacts with cell-division stimulating protein (cdk2). Complexation of p21 and cdk2 halts the cell from passing through the next stage of cell division. If inactivated through mutation p53 is unable to bind to DNA and as a consequence, the p21 protein is not activated and the cells continue to divide uncontrollably to form tumours. 19 The cell actively halts progression through such cell cycle checkpoints as necessary. For the non-biologist, a simple reminder of the cell cycling process is given in Figure 4 . 
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The effects of anti-cancer titanium agents on the cell cycle can be interrogated by use of propidium iodide (PI) a DNA intercalating dye which fluoresces strongly when bound to DNA. The DNA content of an individual cell is directly proportional to the fluorescence intensity of excited PI. A histogram of the DNA content of cells in a population can be used to ascertain what percentage of cells are in each phase of the cell cycle and how test compounds perturb this. Cells are permeabilised by fixation or through the use of a gentle detergent/hypotonic solution in order to allow the PI entry to the cell (to intercalate its DNA). The sub-G 1 peak can be used as an indication of the proportion of the total cell population which possess hypoploid § DNA content indicative of cells undergoing apoptosis. Ovarian A2780 tumour cells treated with 1 (1 mM, 1.75 x IC 50 ) showed S block (+30% at 15 h) and G2-M block (+23% at 24 h). However, at both earlier (6 h) and later (48 h) the cell cycle distributions are essentially identical to control cells, implying that the cell recovered to normal cycling after a short period after agent 1 exposure. 11 Interestingly, cell cycle studies at different intervals after agent 1 exposure (6, 12, 24 and 48 h) in both prostate cancer cell line PC3 and prostate normal epithelial cell line PwR-1E do not reveal any significant effect on the ratio of G 1 , S, or G 2 phases of the cell cycle. 11 Characterisation of the cell death pathway induced by closely related titanocenes X and Y (2-3, Figure 5 ) in A431 cells revealed anti-proliferative activity through cell cycle arrest, ultimately resulting in apoptosis. Titanocene X and Y caused G 2 /M block with a concomitant induction of apoptosis. In contrast, cisplatin treatment of the same cell line results in cell cycle arrest at S phase (inability to duplicate DNA due to cisplatin-DNA induced adducts), further suggesting that the apoptotic effects of 2-3 occurs via alternative mechanisms. Typically degradation of the cellular constituents initiated by PCD is achieved by a group of caspase enzymes (cysteine proteases) that break down the cellular proteins and peptides.҂ Caspases can be activated through two-distinct but convergent pathways, the intrinsic (mitochondria-mediated pathway) and the extrinsic (death receptor-mediated) pathway ( Figure 6 ). Specific transmembrane tumour necrosis factor receptors (TNF) mediate the extrinsic apoptotic route. In the early stages of apoptosis, plasma membrane cell surface changes result in the translocation of the phospholipid phosphatidylserine (PS) from the inner side to the outer layer of the plasma membrane ( Figure 7) . Thus, PS becomes exposed at the external surface of the cell. The Ca 2+ dependent phospholipid binding protein Annexin V has a high affinity for PS, thus can be utilised as a sensitive probe for PS exposure at the external surface of the cell. During the initial stages of apoptosis, the cell membrane remains intact but later, the cell membrane loses its integrity and becomes 'leaky'. Therefore, the stages of cell death can be determined by flow cytometry using Annexin V as a measurement of cell surface binding in conjunction with a dye exclusion test (e.g. fluorescent dyes such as propidium iodide, PI) that determines whether cell membrane integrity is lost. Thus, apoptotic (dying) or necrotic cell populations can be distinguished from healthy cells, which do not bind Annexin V and exclude PI. 
Recent findings in titanium anti-cancer 'mode(s) of action'
Hydrolysis of 1 and its simple derivatives to protein-bound 'ligandless' Ti-species seems to offer a straight forward process for the delivery of titanium into the cell (where its death is subsequently triggered). In an attempt to avoid the hydrolytic complexity of 1 Valentine 25 and Tshuva 2 introduced the use of multi-dentate complexes of the type 4-5 ( Figure 8 ). These species are rather more persistent in aqueous solution and their behaviour is not in accord with the involvement of the serum proteins Tf or SA as titanium transport vectors into the cell. scavenger and this might adversely affect cancer cells disproportionately due to their greater metabolic iron requirement. 26 In comparison to 4, compound 5 shows higher stability.
The fact that hydrolysis of 1, and related metallocenes, generates macroscopic insoluble Ti-based particulates (especially at longer time periods, ~d ays) can allow an alternative mechanism for titanium uptake/signalling via cellular particle envelopment (phagocytosis). Using model 20-30 nm TiO 2 spheres Rashkow showed a Gaussian distribution of titanium burdens within SK-BR-3 breast cancer cells with an average of 26 picomol Ti/cell after exposure (range 0-1.7 nanomol/cell). 27 Interestingly, none of the resulting intracellular TiO 2 particulates (100-8000 nm in size) become associated with the nucleus but some are present in intracellular vacuoles. Studies of related 'sheet-forms' of TiO 2 of dimensions 400 × 2 nm also induced the formation of vacuoles and triggered both paraptosis and apoptosis in mouse-derived white blood lung cells (MH-S) when so treated (24 h, 10-20 μg ml -1 , effective equivalent Ti concentration 0.1-0.2 μM; but only 20% growth inhibition was attained). 18 Interestingly, larger TiO 2 spheres (~1000 nM diameter) do not induce paraptosis.
One potential way to answer the question: "what causes the biological activity -true homogeneous titanium complexes or heterogeneous (and potentially ligandless) precipitates?" is through the use of chiral titanium complexes. Because of innate stereodiscrimination in biological receptors enantiomer dependent biological outcomes if triggered by truly homogeneous species, but not in hydrolysis and/or precipitation has taken place. In principle, the same approach is applicable to both titanocene dichloride complexes or heteroatom ligated Ti(IV) complexes as in the examples of Figure 9 . Enantiopure titanocene dichlorides, that also demonstrate significant anti-cancer activity, are limited to (6) attained through asymmetric catalysis. 28 The (S,S) enantiomer of 6 is significantly more cytostatic to MDA-MB-468 cells (GI 50 11 μM, 24 h), than (R,R)-(6) which delivers weaker growth inhibition (GI 50 2 Ti=O] n species. The latter is also biologically active (GI 50 5.5 μM against MDA-MB-468) but this is independent of the enantiomer of 6 used at 72 h exposure. 28 One explanation is that the later activity is related to the 'heterogeneous' anti-cancer activity shown by sheet TiO 2 (see above   18 ). The chiral 'salan-based' complexes of Tshuva and Manna show equally intriguing behaviour. 29 The separate enantiomers of (7) Figure 7 ), or even trimeric species, that are the putative active anti-cancer agents have been suggested to account for the behaviour of (7) (8) . Fitting this picture those 'salan-based' complexes that are the most hydrolytically stable often exert the poorest biological performance. The inactivity of the isolated dimers (e.g. 9) was not at all consistent with such pictures.
However, this appears to be an artefact caused by their poor aqueous solubility -when formulated as colloidal suspensions (average diameter 18 nm) activity against HT-29 was re-established [IC 50 13 μM]. Please do not adjust margins
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In 2009 Huhn reported that 10-11 were able to induce high cytotoxicity toward cervix tumour HeLa S3 cells ( Figure 10 ). 30 Highly selective apoptotic (˃95%) induction was attained for 10, whereas necrosis accounted for ~5 0% cell death with 11. Salan-based-Ti IV complexes of formula 12 were also reported to be highly active against various tumour cell lines but also against cisplatin-resistant human ovarian cancer cell lines (A2780CisR) and multi-drug resistant (ABCB1-expressing) mouse lymphoma cell lines HU-1 and HU-2. Such findings suggest that salan-based complexes are unaffected by cisplatin/multi-drug resistance mechanisms, and may provide further evidence against direct DNA coordination by such Ti ( Cell cycle arrest at G 1 was observed in both HT-29 and A2780 cell lines following LTi(OiPr) 2 addition, suggesting an alternative mechanism of action compared to that of 1 (cell cycle mostly unaffected) and titanocene Y (3), which blocked cells at the G 2 /M phase. Following incubation with LTi(OiPr) 2 , a significant increase in the p53 levels was observed in both cell lines whilst p21 was only detected in A2780 cells. Cleaved caspase 9 was also detected in both cell lines suggesting a caspase dependent apoptotic pathway. Cellular accumulation of titanium in HT-29 and A2780 cells evidenced a gradual increase in accumulation in both cell lines as a function of agent incubation time. Comparison of the activity of 13 against the NCI-60 cell line panel reveals a unique profile suggesting that the mechanism of action of the titanium complex is distinct, and is not reflected in existing anti-cancer agents. 32 Finally, direct comparison of titanium Y (3) and 'salan-based' complexes indicates that their mechanisms of action are different in MCF-7 and HT-29 cell lines. For Ti-Salan-based species experiments revealed a slow but steady accumulation of titanium in the mitochondria after extended exposure (24 h). On the other hand, intracellular experiments following titanocene Y (3) exposure revealed only low levels thereby indicating that the bio-distribution of Ti in the cells is dependent on the Ti(IV) complex. 33 Such studies indicate that biophysical studies, while vital, can only provide a partial picture in such biochemically complex systems and that use of the full range of modern synthetic biology tools need to be deployed to provide comprehensive understanding. For this reasons both of these are overviewed in context next.
Contemporary tools for determining titanium 'mode(s) of action'
In biology, a mode of action describes a functional or anatomical change, at the cellular level, resulting from the exposure of cells or a living organism to a test agent or drug. In comparison, a mechanism of action describes perturbations at the molecular level. Initial light, bright field, fluorescence, microscopy, to determine morphological changes wrought by treatment of cells with test agents is a critical step and the first indication that agent under scrutiny is having an observable effect on cells. For example, the early observation of Köpf-Maier showing that Ehrlich ascites cells following treatment with 1, underwent dramatic swelling although strongly indicative of necroptosis/paraptosis remained largely uncommented upon. 3 Recent developments in elucidation of the ideal instrumentation allowed easier identification of cellular modes of activation. 28 Modern confocal and super-resolution microscopy 34 can be utilised to probe mechanisms of action for example, individual γH2AX foci (visible sites of DNA damage) can be defined at areas of DNA double strand breaks but are not always informative, e.g. in Tinoco's studies the morphology of A549 was unaffected by treatment with 4. 25 Although higher resolution electron microscopy (scanning, transmission) is able to resolve cellular organelles in fine detail current associated EDAX detectors are not sensitive enough for titanium detections at the very low levels present in cells. Synchrotron-induced fluorescence offer better opportunities -but exact quantification is an issue. As seen in Section 2, through cells labelled with different fluorochromes flow cytometry (FC) offers the simplest way to attain multiparameter analysis of different cellular components or processes on a cell-by-cell basis. A number of analyses may be performed by flow cytometry including determination of cell cycle distribution, apoptosis, γH2AX quantification and reactive oxygen species generation in routine experiments easily carried out by chemical scientists. [34] [35] [36] [37] When faced with a test agent whose activity has been validated, yet whose mechanism of action is unknown a number of interrogative techniques are available, some of which are briefly discussed here.
Reacting to the explosion in kinase inhibitor research, highthroughput (HTP) kinase profiling has been developed by many
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Please do not adjust margins organisations. The activity of hundreds of kinases can be compared in lysates of compound-and vehicle-treated cells. Alternatively, cellfree assays offer the opportunity to determine the effect of a given compound on activity of hundreds of kinases. Screens utilise a number of techniques including radiometric and time-resolved fluorescence energy transfer (TR-FRET) analyses. 38, 39 The latter, a combination of time-resolved fluorometry (TRF) and Förster resonance energy transfer (FRET) offers a powerful tool for drug discovery researchers. To validate HTP assays, determination of phosphorylation should be conducted (e.g. Immunoblot profile kits or Western blot as outlined below). Custom screening options are available, in which kinases under investigation and compound concentrations can be selected by the researcher, allowing doseresponse and IC 50 profiles to be generated. The ATP binding site is a common target for kinase inhibitors and thus ATP competition assays can be provided.
Traditionally, proteomics (protein analysis) methodologies have relied upon separation of complex protein mixtures in samples by 2-dimensional gel electrophoresis: by isoectric point and molecular weight. 40 Patterns could be compared, and where changes were evident, protein identification involved isolation of protein spots, proteolysis, and mass analysis of each peptide prior to sequence database searched. Multidimensional Protein Identification Technology (MudPIT) eliminates the need for gel electrophoresis. Biochemical fractions/cell lysates containing many proteins are directly proteolysed and the enormous numbers of peptides generated are separated by 2-dimensional liquid chromatography. Tandem mass spectrometry (LC-MS/MS) is then employed to identify those proteins whose expression has been up-or downregulated by the test agent. 41 Attaining the identity of the exact titanium entity responsible for a specific biological observation is a major challenge as hydrolysis of the precursor complexes typically occurs in the same time frame and distinguishing between soluble and insoluble species has been a recurrent problem in this area. Even in the case of species stable to ligand loss 29 aggregation effects might occur and anti-cancer activity triggered by heterogeneous species is also known.
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Electrospray (ESI) analyses of the complex pro-drug dissolved in its cellular growth medium can provide a way to estimate the total Tispecies present as a function of time. If, in the same time frame, LCMS studies are also carried out disambiguation of solution vs insoluble species can be attained in favourable cases, as the latter are not eluted in the LCMS. For 6 paring such analyses confirmed formation of homogeneous [Cp R Ti(OH)(OH 2 )] + was commensurate with the onset of paraptosis. 28 Disappearance of the latter led to the formation of insoluble precipitates, observed as protonated [Cp R 2 TiO] 2 . Once identified this process could be kinetically modelled with high confidence, even though both the starting 6 and it eventual product are insoluble under aqueous conditions. Kinetic modelling of titanium speciation should be a powerful tool for identifying potential biologically active species -particularly if matched against the onset of biological outcomes. However, as the concentrations of the titanium species involved in real biological systems are low (μM) use of NMR has only recently become practical with the widespread availability of very high field (>600 MHz) instruments.
A powerful tool which facilitates identification of protein targets of aqueous titanium species is offered by genome-wide short hairpin RNA (shRNA) library screens. Whole genome-, custom-and kinasepooled lentiviral library screening is possible. In this technique, cells are transduced with human pooled shRNA library which may target >15000 human genes. Transduced cells are selected by survival in medium supplemented with antibiotic (e.g. 1 μg/mL puromycin; 4 days) before being treated with test agent (e.g. for 72 h). Following isolation of genomic DNA, ShRNA sequences present in each sample are determined by next generation sequencing (NGS). 42, 43 The use of CRISPR Cas9-gRNA complex for genome editing was the American Association for the Advancement of Science's choice for breakthrough of the year in 2015. 49 Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid. The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognise and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. Cas9 was the first nuclease discovered, CRISPR/C2c2 from the bacterium Leptotrichia shahii is an RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down. By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be excised at a desired location, allowing existing genes to be removed and/or new ones to be added. CRISPR/Cas genome editing techniques have many potential applications, including validation of molecular mechanisms of action of drug candidates.
The procedures outlined above are not exhaustive, but provide initial insight into experiments which may be undertaken, and sophisticated techniques which are available to enable elucidation of molecular mechanisms of action of experimental agents, drug candidates and clinical agents. Indeed, the complex genome-wide functional screens introduced, which warrant further reading to impart deeper understanding, have recently led to identification of genes and proteins affecting sensitivity to tamoxifen, a long-established anticancer drug. 50 Genomic approaches maybe particularly profitable in the area of titanium-based anti-cancer agents as, to the best of our knowledge, there is not a reported incidence of cellular resistance developing in cell lines exposed to such agents, a clear distinction from Pt-based agents.
Conclusions: future paths and strategies for titanium therapeutics
It can be concluded from this review that early ideas that titanium dichloride (1), and other related species, would function analogously to cisplatin were far from the 'complete' truth. To date about 10 variously distinct mechanisms of action have been proposed for titanium-based therapeutics including: the triggering of apoptosis via DNA binding, inhibition of mitochondrial activity, induction of paraptosis (via kinase activation), the inactivation of tropoisomerases and cell death by iron deprivation. It is also clear that heterogeneous particulates (nanoparticles), long assumed to be 'unimportant' decomposition products of the homogeneous titanium complexes provided to the cell actually can trigger a wide range of biological outcomes in their own right. Although the presence of such multiple biological activation modes makes understanding the exact behaviour of titanium-therapeutics challenging current chemical and bio-chemical tools are now available making this a tractable proposition. In fact opportunities to target multiple mechanisms of action are to be welcomed as they offer potentially multiple therapeutic pathways to for improve clinical outcomes via combination therapy.
Abbreviation list

BECN1
An important 60 kDa signalling protein in autophagy and other PCD events. BID A 22 kDa signalling protein that stimulates release of cytochrome c from the mitochondria. 
